Role of aminoglycosides in the treatment of bacterial endocarditis

Journal of Antimicrobial Chemotherapy

Volumn 49, Issue 3, 2002, Pages 437-444

  Graham, J C ^a   Gould, F K ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CLOXACILLIN; GENTAMICIN; KANAMYCIN; METICILLIN; NAFCILLIN; NETILMICIN; PENICILLIN DERIVATIVE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG POTENTIATION; DRUG TOXICITY; ENTEROCOCCUS; EVIDENCE BASED MEDICINE; HUMAN; LABORATORY TEST; NEPHROTOXICITY; NONHUMAN; OUTPATIENT CARE; PRACTICE GUIDELINE; STAPHYLOCOCCUS;

EID: 0036120133     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/49.3.437     Document Type: Article

References (63)

1. Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis
2. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms
3. New guidelines for the antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis
4. Treatment of penicillin-sensitive streptococcal endocarditis
5. Chemotherapy of experimental streptococcal endocarditis II. Synergism between penicillin and streptomycin against penicillin-sensitive streptococci
6. Penicillin therapy for treatment of experimental endocarditis caused by viridans streptococci in animals
7. Penicillin-aminoglycoside synergy in experimental Streptococcus viridans endocarditis
8. Treatment of streptococcal infective endocarditis
9. Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin
10. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococi
11. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: A prospective multicenter study
12. Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci
13. High-level aminoglycoside resistance mediated by aminoglycoside modifying enzymes among viridans streptococci: Implications for the therapy of endocarditis
14. In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis
15. In vitro antimicrobial susceptibility of viridans streptococci isolated from blood cultures
16. Report of a Working Party of the British Society for Antimicrobial Chemotherapy. Antibiotic treatment of streptococcal and staphylococcal endocarditis
17. Influence of the pretreatment duration of infection on the efficacies of various antibiotic regimens in experimental streptococcal endocarditis
18. Influence of vegetation size on clinical outcome of right-sided infective endocarditis
19. Antibiotic treatment of infective endocarditis due to viridans streptococci, enterococci and other streptococci
20. Glycopeptide tolerance in bacteria causing enocarditis
21. Synergism with aminoglycosides of penicillin, ampicillin and vancomycin against non-enterococcal group D streptococci and viridans streptococci
22. Comparison of penicillin and vancomycin, individually and in combination with gentamicin and amikacin, in the treatment of experimental endocarditis induced by nutritionally variant streptococci
23. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination
24. Enterococcal endocarditis: A comparison of prosthetic and native valve disease
25. Synergy of penicillin and gentamicin against enterococci
26. Synergy of penicillin and decreasing concentrations of aminoglycosides against enterococci from patients with infective endocarditis
27. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for the treatment of Enterococcus faecalis-induced experimental endocarditis
28. Influence of gentamicin dosing interval on the efficacy of penicillin-containing regimens in experimental Enterococcus faecalis endocarditis
29. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen plus stimulated profiles of ampicillin in human serum
30. Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in-vitro infection model
31. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis
32. Enterococcal endocarditis: Duration and mode of treatment
33. Optimal therapy for enterococcal endocarditis
34. Enterococcal endocarditis
35. Aminoglycoside resistance in enterococci
36. Antibiotic synergism of enterococci
37. Antibiotic resistance among enterococci causing endocarditis in the UK: Analysis of isolates referred to a reference laboratory
38. Vancomycin-streptomycin synergism in enterococcal endocarditis
39. Teicoplanin in the treatment of enterococcal endocarditis: Clinical and microbiological study
40. Antibiotic treatment of Staphylococcus aureus endocarditis. A review of 119 cases
41. Combination antibiotic therapy of bacterial endocarditis
42. Enhancement of the effects of anti-staphylococcal antibiotics by aminoglycosides
43. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus
44. Role of tolerance in cloxacillin treatment of experimental Staphylococcus aureus endocarditis
45. Significance of methicillin tolerance in experimental staphylococcal endocarditis
46. Clinical significance of tolerant strains of Staphylococcus aureus in patients with endocarditis
47. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts
48. Treatment of Staphylococcus aureus endocarditis: An analysis based on 25 proven cases
49. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided Staphylococcus aureus endocarditis
50. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: Two-week combination therapy
51. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis
52. Short-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: Cloxacillin versus glycopeptides in combination with gentamicin
53. Staphylococcal endocarditis-recommendations for therapy
54. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
55. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis
56. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis
57. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis
58. Therapy for experimental endocarditis due to Staphylococcus epidermidis
59. Staphylococcus aureus prosthetic valve endocarditis: Optimal management and risk factors for death
60. Staphylococcus epidermidis causing prosthetic valve endocarditis: Microbiological and clinical observations as guides to therapy
61. Endocarditis and intravascular infections
62. Infective endocarditis caused by β-hemolytic streptococci
63. Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: Case report and review